Search

everythinglearnresearchcommunity

for

Search:↓

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Herbal products for benign prostate hypertrophy need better quality checks to ensure safety and effectiveness.

Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.

More prostate biopsies increase the chance of finding cancers that may not need treatment.

DHT in the human prostate is produced through multiple pathways, not just from testosterone.

Hormones and metabolism play a complex role in prostate enlargement, and more research is needed to improve diagnosis and treatment.

Finasteride may reduce prostate bleeding by lowering blood vessel growth factor levels and blood vessel density in certain prostate areas.

Wedelolactone selectively kills prostate cancer cells without harming normal cells.

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.

Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Finasteride effectively reduces prostate size and lowers surgery risk in men with benign prostatic hyperplasia.

The normal human prostate does not significantly affect blood DHT levels.

Circadian rhythm disruption, chronic inflammation, hormones, metabolism, and genetics may increase prostate cancer risk.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.

New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.

Urban living may increase prostate cancer risk, while early sexual activity might reduce it.

Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.

More research and guidelines are needed for managing prostate cancer in people with high-risk genetic mutations.

Treatment for benign prostatic hyperplasia involves drugs that either quickly relieve symptoms or reduce prostate size, with a combination offering more benefits but more side effects.

Treatments for enlarged prostate can cause problems with ejaculation, and less invasive options might preserve sexual function better.

Saw palmetto supplements may reduce prostate cancer cell growth without being toxic.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

Diabetes may lower the risk of prostate cancer.

Dutasteride may help shrink prostate cancer tumors.

Older age and prostatic hyperplasia in males increase the risk of hemorrhagic cystitis after stem cell transplantation.

Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.